Rebranding Lipophilic Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rebranding Lipophilic Excipients
Streamlining the structure, nomenclature and functionality of excipients


Pharmaceutical Technology Europe
Volume 24, Issue 9


Table I: Kolliphor® grades.
Solubilizers play an important role in dissolving poorly soluble molecules. As the number of poorly soluble lipophilic and/or hydrophobic molecules increases—whether as "brick dusts" or waxy substances—the industry is struggling to identify the appropriate lipophilic excipients (surfactants, solubilizers, solvents or polymers) that can be used to develop such poorly soluble formulations into solid dosages and other forms of pharmaceutical products. Furthermore, the complexity of such formulations is increasing and often two or more solubilizers and/or cosolvents are required to develop stable and efficacious formulations with enhanced bioavailability (1).


Table II: Kollisov® grades.
As pharmaceutical manufacturers develop generic and new molecules that require high-quality, functional excipients, they seek support from excipient manufacturers. Indeed, the pharmaceutical industry relies on excipient manufacturers to design and produce excipients that are appropriate to the envisaged dosage form and API. This is a complex undertaking made all the more difficult because of the number of different names that manufacturers use for their excipients. However, several excipient manufacturers are now streamlining the structure, nomenclature and functionality of their excipients, including solubilizers.


Table III: Kolliwax® grades.
Such rebranding has been used in other industries to reduce complexity and to promote products on the merits of their performances and qualities, ideally without undermining the old brands. This is now occurring among excipient manufacturers, particularly those that carry lipophilic excipients, including BASF, as well as other companies. Many companies have used branding and rebranding to either introduce new products or reintroduce an old product under a single 'prefix' to simplify identification. In the case of BASF, Cremophor®, Solutol®, Lutrol® and other solubilizers will become part of the Kolliphor® brand family.


Table IV: Kollicream® grades.
The basis for rebranding with the same prefix is to identify molecules by structures, functions and the applications of choice; enable the company's brand products to be recognized; and to differentiate pharmaceutical excipients from other grades. Rebranding is a tedious and time-consuming process, and in some instances adds complexity if the functionality of the molecule is not well defined.

Here, we provide a synopsis of how we have undertaken the process of rebranding our solubilizers for pharmaceutical applications. With a few exceptions, we have tried to preserve some of the characters from the old product brand name to avoid confusion and to allow scientists to easily recognize them. The surfactants and solubilizers, as well as related products, have been categorized under four umbrella rebranding subgroups:

  • Kolliphor: For amphiphilic substances such as ionic and non-ionic surfactants, solubilizers and emulsifying agents, as shown in Table I.
  • Kollisolv: For solvents such as mediumchain triglycerides, propylene glycol, liquid polyethylene glycols and liquid poloxamers, as shown in Table II.
  • Kolliwax: This name was coined to represent consistency factors, such as those in fatty acids, alcohols and glycerides, as shown in Table III.
  • Kollicream: The name was chosen to represent emollients such as fatty acid esters and special fatty alcohols, as shown in Table IV.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here